Analyst consensus rating
MapLight Therapeutics Analyst Rating: Strong Buy
Direct answer
MapLight Therapeutics's consensus rating is Strong Buy.
13 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $26.54.
Forecast evidence checked October 14, 2026.
Get free MapLight Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $7.88
- Average price target
- $26.54
- High price target
- $43.00
- Low price target
- $13.00
- Low target gap
- +65.1%
- Target upside
- +237%
- High target gap
- +446%
- Target range width
- 381%
- Consensus rating
- Strong Buy
- Analysts
- 13
- Evidence date
- October 14, 2026
- Valid through
- October 21, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for MapLight Therapeutics?
MapLight Therapeutics has a verified Strong Buy consensus. The same dataset has an average price target of $26.54.
How far are MapLight Therapeutics's low and high targets from the recorded price?
The low target implies +65.1%, while the high target implies +446%.
How many analysts are included in MapLight Therapeutics's consensus?
The verified consensus includes 13 analysts.
How is MapLight Therapeutics's target upside or downside calculated?
The average target of $26.54 is divided by the recorded price of $7.88, then one is subtracted to produce +237%. This does not guarantee a future return.
When was MapLight Therapeutics's analyst forecast verified?
The data was verified on 2026-10-14. The dataset is valid through 2026-10-21.